FORM PTO-1449 MODIFIED U.S. IS RETMENT OF COMMERCE PATENT AND TRADEMARK OFFICE 420 INFORMATION DISCLOSURE STATEMENT BY APPLICANT						ATTY. DO T NO. 175931 Rec'd PCT/PTO 23 NOV 1999 APPLICANT Mitchell et al.					
(Use several sheets if necessary)					FILING DATE Novemver 23, 1999			GROUP Unassigned			
		U.S. PAT	TENT DOCUMEN	TS				T			
	PATENT Number	ISSUE DATE	Name	CLASS		Subci	SUBCLASS		FILING DATE IF APPROPRIATE		
					1						
	DOCUMENT		PATENT DOCUM	MENTS		T		TRAN	SLATION		
	Number	DATE		,	CLASS	SUBCLASS		YES	No		
AA	WO 96/40127	Dec. 19, 1996	WIPO		-+-	+					
			 			+	· -	-			
						1 1			 		
	_										
							_	<u> </u>	<u> </u>		
	OTHER DO	CUMENTS (Inclue	ding Author, Title,	Date, Po	ertinent Pag	ges, Etc.)					
AB	Monti et al., "Cytotoxicity of Tempol, a Piperidine Nitroxyde Spin Label, Against Different Neoplastic ar Non-Neoplastic Cell Lines," PAACR Annual Meeting, 36, 387 (1995).										
	Tempol," PAACR Annual Meeting, 38, 193 (1997).										
AD					ptosis and	P21-WAI	F1-CI	P1 Express	ion in P		
	(U	PATE NFORMATION DISCLO BY APPLIC (Use several sheets PATENT NUMBER DOCUMENT NUMBER AA WO 96/40127 OTHER DO AB Monti et al., "C Non-Neoplastic AC Monti et al., "D Tempol," PAAC AD Monti et al., "TI	PATENT AND TRADE NFORMATION DISCLOSURE STATEME BY APPLICANT (Use several sheets if necessary) U.S. PATENT NUMBER PATENT NUMBER ISSUE DATE FOREIGN DOCUMENT NUMBER DATE AA WO 96/40127 Dec. 19, 1996 OTHER DOCUMENTS (Inclued and Monti et al., "Cytotoxicity of Tement Non-Neoplastic Cell Lines," PAAC AC Monti et al., "The Piperidine Nitro Monti et al., "The Piperidine Nitro Monti et al., "The Piperidine Nitro	PATENT AND TRADEMARK OFFICE 420 NFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) U.S. PATENT DOCUMEN PATENT NUMBER ISSUE DATE NAME FOREIGN PATENT DOCUMEN POCUMENT NUMBER DATE COUNTRY AA WO 96/40127 Dec. 19, 1996 WIPO OTHER DOCUMENTS (Including Author, Title, AB Monti et al., "Cytotoxicity of Tempol, a Piperidine Non-Neoplastic Cell Lines," PAACR Annual Meeting AC Monti et al., "The Piperidine Nitroxyde Tempol-Indu Tempol," PAACR Annual Meeting, 38, 193 (1997). AD Monti et al., "The Piperidine Nitroxyde Tempol-Indu	PATENT AND TRADEMARK OFFICE 420 NFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) U.S. PATENT DOCUMENTS PATENT NUMBER ISSUE DATE POCUMENTS FOREIGN PATENT DOCUMENTS POCUMENT NUMBER DATE COUNTRY AA WO 96/40127 Dec. 19, 1996 WIPO OTHER DOCUMENTS (Including Author, Title, Date, P.	PATENT AND TRADEMARK OFFICE 420 REC'T PCT/P APPLICANT (Use several sheets if necessary) U.S. PATENT DOCUMENTS PATENT NUMBER ISSUE DATE NAME CLASS FOREIGN PATENT DOCUMENTS POCUMENTS POCUMENT POCUMENT POCUMENT POCUMENT POBLICATION NUMBER AA WO 96/40127 Dec. 19, 1996 WIPO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages) AD Monti et al., "Cytotoxicity of Tempol, a Piperidine Nitroxyde Spin La Non-Neoplastic Cell Lines," PAACR Annual Meeting, 36, 387 (1995). AC Monti et al., "The Piperidine Nitroxyde Propol," PAACR Annual Meeting, 38, 193 (1997). AD Monti et al., "The Piperidine Nitroxyde Empol," PAACR Annual Meeting, 38, 193 (1997). AD Monti et al., "The Piperidine Nitroxyde Tempol," PAACR Annual Meeting, 38, 193 (1997).	PATENT AND TRADEMARK OFFICE 420 NFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) U.S. PATENT DOCUMENTS PATENT NUMBER ISSUE DATE NAME CLASS SUBCI FILING DATE Novemver 23, 1999 U.S. PATENT DOCUMENTS PATENT NUMBER ISSUE DATE NAME CLASS SUBCI FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE AA WO 96/40127 Dec. 19, 1996 WIPO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) AB Monti et al., "Cytotoxicity of Tempol, a Piperidine Nitroxyde Spin Label, Agair Non-Neoplastic Cell Lines," PAACR Annual Meeting, 35, 387 (1995). AC Monti et al., "The Piperidine Nitroxyde Tempol-Induced Apoptosis and P21-WAI AD Monti et al., "The Piperidine Nitroxyde Tempol-Induced Apoptosis and P21-WAI AD Monti et al., "The Piperidine Nitroxyde Tempol-Induced Apoptosis and P21-WAI AD Monti et al., "The Piperidine Nitroxyde Tempol-Induced Apoptosis and P21-WAI	PATENT AND TRADEMARK OFFICE 420 NFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) U.S. PATENT DOCUMENTS PATENT NUMBER PATENT NUMBER PATENT NUMBER POCUMENTS POCUMENTS POCUMENT POCUMENT POCUMENT POCUMENT NUMBER DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) AB Monti et al., "Cytotoxicity of Tempol, a Piperidien Nitroxyde Spin Label, Against Dit Non-eoplastic Cell Lines," PAACR Annual Meeting, 38, 193 (1997). AD Monti et al., "DNA Damage and Apoptosis in Human Leukemic Cells Treated with the Tempol," PAACR Annual Meeting, 38, 193 (1997). AD Monti et al., "DNA Damage and Apoptosis in Human Leukemic Cells Treated with the Tempol," PAACR Annual Meeting, 38, 193 (1997).	PATENT AND TRADEMARK OFFICE 420 FORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) FILING DATE Novemver 23, 1999 Unassigned U.S. PATENT DOCUMENTS PATENT NUMBER ISSUE DATE NAME CLASS SUBCLASS APPRE FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS POCUMENT NUMBER DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRAN YES OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) AB Monti et al., "Cytotoxicity of Tempol, a Piperidine Nitroxyde Spin Label, Against Different Nec Non-Neoplastic Cell Lines," PAACR Annual Meeting, 36, 1387 (1995). AC Monti et al., "Taylo Daringe and Apoptosis in Human Leukemic Cells Treated with the Piperidine Tempol," PAACR Annual Meeting, 38, 139 (1997). AD Monti et al., "The piperidine Nitroxyde Tempol, a PataCR Annual Meeting, 38, 139 (1997). AD Monti et al., "The piperidine Nitroxyde Tempol," PIAACR Annual Meeting, 38, 139 (1997). AD Monti et al., "The piperidine Nitroxyde Tempol," PIAACR Annual Meeting, 38, 139 (1997). AD Monti et al., "The piperidine Nitroxyde Apoptosis and P21-WAF1-CIP1 Express		

DATE CONSIDERED

1-23-01

EXAMINER

^{*}A concise statement of relevance is being submitted in lieu of a translation. 37 CFR § 1.98(b). 1449FORM (Rev. 7/15/1999)